Chimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma trial
Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company’s lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial. Tim McGowen: Today we’re talking with Chimeric Therapeutics (ASX:CHM). Market cap of around $16m. We have with us the CEO and Managing Director, Jennifer Chow. […]
Chimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma trial Read More »